Logo

FDNA

PerkinElmer, FDNA Combine Genomic Service, Phenotyping Technology to Improve Rare Disease Diagnosis
Premium

The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.  

FDNA, PerkinElmer Form Genetic Testing Technology Alliance

FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.

Pronto Diagnostics Plans to Integrate FDNA's Phenotypic Analysis Into Its Genetic Tests

The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.

Vanderbilt Medical Center to Use FDNA Technology for Disease Diagnosis

The Vanderbilt Center for Undiagnosed Diseases will use FDNA's Face2Gene to help evaluate difficult-to-diagnose patients.

PreventionGenetics to Integrate FDNA's Face2Gene Into DNA Testing Services

PreventionGenetics will use FDNA's technology to expand the diagnostic ability of its testing and interpretation services.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.